Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement

Yasuto Yoneshima, Isamu Okamoto, Masako Arimura-Omori, Shinichi Kimura, Noriko Hidaka-Fujimoto, Eiji Iwama, Taishi Harada, Koichi Takayama, Yoichi Nakanishi

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Crizotinib is the first clinically available tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK) and is associated with the development of complex renal cysts. We now describe a 39-year-old woman who developed infected complex renal cysts during crizotinib treatment. After 10 months of such treatment, she presented with a high fever and low back pain. Computed tomography findings were consistent with complex renal cysts and perilesional inflammation. Interventions including cyst drainage and antibiotic administration contributed to diagnosis and management of the infected cysts.

Original languageEnglish
Pages (from-to)510-512
Number of pages3
JournalInvestigational New Drugs
Volume33
Issue number2
DOIs
Publication statusPublished - Apr 1 2015

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement'. Together they form a unique fingerprint.

Cite this